NRX Pharmaceuticals, Inc. Retained Earnings
NRX Pharmaceuticals, Inc. (NRXP) had Retained Earnings of -$324.85 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$324.85M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$308.32M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$306.89M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$307.26M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$324.85M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$308.32M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | -$306.89M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$307.26M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$301.37M 10-Q · filed 2025-08-18 | |
| 2025-03-31 | -$283.79M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$278.27M 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$269.19M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$267.57M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$259.68M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$253.15M 10-K · filed 2025-03-14 | |
| 2023-09-30 | -$248.81M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$242.75M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$234.04M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$223.00M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$212.76M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$203.67M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$196.69M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$183.24M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$152.84M 10-Q/A · filed 2022-08-12 | -$152.45M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$115.79M 10-Q/A · filed 2022-08-12 | -$131.68M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$1.61M 10-Q · filed 2021-05-21 | |
| 2020-12-31 | -$90.18M 10-Q/A · filed 2022-08-12 | -$64.92K 10-K · filed 2021-04-01 |
| 2020-09-30 | $367.44K 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $493.21K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $642.72K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $369.50K 10-K/A · filed 2021-05-14 | |
| 2019-09-30 | $384.25K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $325.05K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $149.03K 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$38.93K 10-K · filed 2020-03-30 | |
| 2018-09-30 | -$68.07K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$96.15K 10-Q · filed 2018-08-08 | |
| 2018-03-31 | -$89.55K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$105.03K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |